Analysis of the primary outcome in prespecified subgroups showed a consistent benefit of canagliflozin treatment compared with non‐SGLT2i among each of the subgroups based on sex, age, insulin or GLP‐1 receptor agonist use in the past 12 months, history of heart failure, HHF in the past 12 months, number of cerebrovascular risk factors and renal disease, with no between‐subgroup heterogeneity detected (Figure S4). The gene discussed is INS; the disease is kidney disorder.